Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clopidogrel resistance: implications for coronary stenting.

Paul A Gurbel1, Wei C Lau, Kevin P Bliden

  • 1Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA. Pgurbel@lifebridgehealth.org

Current Pharmaceutical Design
|April 14, 2006
PubMed
Summary

Clopidogrel resistance and high platelet reactivity increase risks for thrombotic events after stent implantation. Further research is needed to understand the clinical impact and cost-effectiveness of assessing platelet inhibition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TEG ® 6s Heparin Neutralization Cartridge for Hemostatic Assessment of Patients Undergoing Cardiovascular Surgery.

Anesthesiology·2025
Same author

Machine Learning Predicts Bleeding Risk in Atrial Fibrillation Patients on Direct Oral Anticoagulant.

The American journal of cardiology·2025
Same author

Reassessing the role of aspirin in patients with coronary artery disease.

Expert opinion on pharmacotherapy·2024
Same author

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.

Kardiologia polska·2024
Same author

New interest in fibrinogen as an ischemic risk factor.

Journal of thrombosis and thrombolysis·2024
Same author

Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome.

Expert opinion on pharmacotherapy·2024

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Clopidogrel with aspirin is standard for preventing thrombosis post-coronary stent implantation.
  • Current practice administers clopidogrel without assessing platelet inhibition, despite known response variability and resistance.
  • Patients with nonresponsive platelets may face increased thrombotic event risk, though this is under-investigated.

Purpose of the Study:

  • To investigate the relationship between clopidogrel resistance, high platelet reactivity, and thrombotic events (stent thrombosis, myocardial infarction, stroke, death).
  • To determine if a threshold of platelet reactivity predicts thrombotic risk.
  • To assess the cost implications of treating non-responsive patients with clopidogogrel.

Main Methods:

Related Experiment Videos

  • The study aims to address key questions regarding clopidogrel response and clinical outcomes.
  • It emphasizes the need for validated point-of-service devices to facilitate understanding.
  • Mechanisms underlying clopidogrel response variability are under investigation.

    • Main Results:

    • Preliminary data suggest a link between clopidogrel nonresponsiveness and thrombotic event risk.
    • The magnitude of this clinical effect and specific risk thresholds remain largely unknown.
    • The cost-effectiveness of current clopidogrel administration strategies is not fully elucidated.

    Conclusions:

    • Understanding clopidogrel resistance and high platelet reactivity is crucial for optimizing patient outcomes after stent implantation.
    • Further research is required to define clinical relevance, establish risk thresholds, and evaluate cost-effectiveness.
    • Investigating the mechanisms of response variability is essential for improving antiplatelet therapy.